Our Partners

Our Partners

Our Partners

Most new immunotherapies are developed collaboratively by academic institutions, SMEs and large pharmaceutical companies. So this vital innovative element of tight networking in product-oriented regional project networks made up of various different partners is an essential part of the Ci3-strategy. The current 37 partners of the 28 research and development joint projects are closely linked to each other and form the core of the Ci3-leading-edge cluster. In addition to the collaborative projects, a total of approximately 120 partners from industry-specific SMEs and large corporations as well as academic research and educational institutions, associations, policy makers and the general public are linked through the Ci3-cluster.

Organizations